Addiction

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

Retrieved on: 
Wednesday, October 5, 2022

NEW YORK and BERLIN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing VLS-01, a form of N,N-dimethyltryptamine (DMT) for the treatment of treatment-resistant depression (TRD), announced today the dosing of the first subject in their Phase 1 SAD trial of VLS-01.

Key Points: 
  • - atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023.
  • - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) under development for treatment-resistant depression (TRD) in combination with atais digital therapeutic designed to provide contextual (mind)set-and-setting support to patients prior to dosing.
  • NEW YORK and BERLIN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (atai), which is developing VLS-01, a form of N,N-dimethyltryptamine (DMT) for the treatment of treatment-resistant depression (TRD), announced today the dosing of the first subject in their Phase 1 SAD trial of VLS-01.
  • atai anticipates Phase 1 topline results in H1 2023.
    atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day

Retrieved on: 
Tuesday, October 4, 2022

Archived webcasts will be accessible in the Events section of atais website where they will be available for up to 90 days.

Key Points: 
  • Archived webcasts will be accessible in the Events section of atais website where they will be available for up to 90 days.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
  • atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
  • Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements.

Envision Healthcare Provides Best Practices to Address America’s Devastating Opioid Epidemic

Retrieved on: 
Friday, September 30, 2022

Envision Healthcare, a leading national medical group, released a comprehensive strategy to address Americas pervasive opioid epidemic.

Key Points: 
  • Envision Healthcare, a leading national medical group, released a comprehensive strategy to address Americas pervasive opioid epidemic.
  • In 2020 alone, opioids were involved in 68,630 overdose deaths nearly 75 percent of all drug overdose deaths.
  • Additionally, the marked expansion of illicitly manufactured, potent synthetic opioids has flooded the U.S. with lethal counterfeit opioid pain pills, increasing the danger of non-prescribed opioids.
  • We are pleased to provide a patient-focused strategy to help stop opioid misuse and abuse and save peoples lives.

Webinar Series Continues by Commemorating Statewide Knock Out Opioid Abuse Day

Retrieved on: 
Thursday, September 29, 2022

Millburn, NJ, Sept. 29, 2022 (GLOBE NEWSWIRE) -- MILLBURN The Knock Out Opioid Abuse Day Learning Series will continue this month with a special webinar focusing on addiction recovery to commemorate Knock Out Opioid Abuse Day, a statewide initiative to raise public awareness about the opioid epidemic and to mobilize prevention and treatment communities.

Key Points: 
  • Millburn, NJ, Sept. 29, 2022 (GLOBE NEWSWIRE) -- MILLBURN The Knock Out Opioid Abuse Day Learning Series will continue this month with a special webinar focusing on addiction recovery to commemorate Knock Out Opioid Abuse Day, a statewide initiative to raise public awareness about the opioid epidemic and to mobilize prevention and treatment communities.
  • The webinar, Knock Out Opioid Abuse Day: Where We Stand & How We Move Forward, will be held at 11 a.m. Thursday, October 6.
  • This webinar will be the 10th in the 2022 Knock Out Opioid Abuse Day Learning Series .
  • The next webinar, Knock Out Opioid Abuse Day, will be held at 11 a.m. Thursday, October 6.

2B3D Shares Addiction Treatment Deliverables from BioCorRx for Phase I of Mental Health Metaverse Platform Beta

Retrieved on: 
Thursday, September 29, 2022

Los Angeles, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – 2B3D, a military veteran-operated mental health technology solutions firm specializing in VR, Gaming, NFTs, developing metaverse solutions for PTSD and addiction treatment, today announced the scope of deliverables from its addiction treatment partner, BioCorRx.

Key Points: 
  • 2B3Ds end-to-end prototype for live, free PTSD treatment for military veterans allows platform users to self-identify addiction issues upon first arrival in the VR Medical Environment (VRME).
  • BioCorRxs course modules are a popular and well-tested component of the firms Beat Addiction Recovery Program, a non-metaverse treatment therapy that is largely app-driven.
  • In 2B3Ds metaverse, military veterans will be able to reach out to mental health professionals using a customized avatar for more personalized online interactions.
  • BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.

The Recovery Cycle: A Contemporary Guidebook that Blasts Open the Blocks That Keep Sober People from Reaching Their Greatest Potential Releases Today!

Retrieved on: 
Thursday, September 29, 2022

LOS ANGELES, Sept. 28, 2022 /PRNewswire/ -- The Recovery Cycle: A Practical Guide to Loving Your Sober Life, offers a fresh and unique perspective for recovery from all substance and behavioral addictions – written for recovering individuals and clinicians. Check out the reviews at the end.

Key Points: 
  • Enter The Recovery Cycle, a timeless navigation tool that guides readers to explore and design a new life with freedom and limitless expansion - and it works with any program!
  • Engaging in style, the book introduces 4 essential principles that gently ask the reader to participate in their own vision of recovery.
  • This book stimulates and reinforces the kind of courageous living and loving required to thrive in this expansive, conscious, sober existence.
  • "Beautifully written, engaging, inspirational a love song to the freedom, creativity, and ever-evolving joys of recovery."

Seen Through Horses Campaign Presented by Zoetis Garners Celebrity and Influencer Support

Retrieved on: 
Tuesday, September 27, 2022

Seen Through Horses Campaign is the first convening campaign of its kind focused on mental health through horses.

Key Points: 
  • Seen Through Horses Campaign is the first convening campaign of its kind focused on mental health through horses.
  • Horses are adept at sensing emotions and have the ability to connect with humans on a deep level.
  • As Seen Through Horses Campaign galvanizes equine and mental health communities around one goal, espoused at the same time, choose a nonprofit organization to support from Oct. 3-10, 2022, by visiting www.horsesformentalhealth.org/campaign , Instagram @horsesformentalhealth , Facebook @horsesformentalhealth and @zoetisequine .
  • If horses have impacted your life, mental health, or personal journey, please share your story and tag us.

LA Goes Psychedelic September 30

Retrieved on: 
Tuesday, September 27, 2022

LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via InvestorWire The Psychedelic Institute is convening the first major psychedelic conference to be held in Los Angeles on Friday, September 30, at the Founders Church of Religious Science, 10 AM 6 PM!

Key Points: 
  • LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via InvestorWire The Psychedelic Institute is convening the first major psychedelic conference to be held in Los Angeles on Friday, September 30, at the Founders Church of Religious Science, 10 AM 6 PM!
  • Awakening of Consciousness will offer the public an opportunity to hear, meet, and learn from 30 of the world's leading researchers, healers, and activists working in the field of psychedelics and plant medicine.
  • Awakening of Consciousness features 18 general session speakers, 5 panel discussions and 7 participatory workshops.
  • Experts will illuminate the vast potential of psychedelic medicine to heal trauma, addiction, depression, and anxiety and highlight the progress being made in regulatory approval, access, clinical results, and therapies.

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

Key Points: 
  • Evidence shows that two-thirds of patients either do not respond or have only a partial response to these medications.
  • These modifications are designed to separate the entactogenic effects of MDMA from some of the known side effects, specifically its stimulant-associated effects.
  • Data on MDMA-assisted psychotherapy strongly suggests its potential for the treatment of PTSD, said Glenn Short, Senior Vice President, Early Development of atai Life Sciences.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Retrieved on: 
Monday, September 26, 2022

The interim data available from Part B include pharmacokinetics, key pharmacodynamic outcomes, and blinded safety data.

Key Points: 
  • The interim data available from Part B include pharmacokinetics, key pharmacodynamic outcomes, and blinded safety data.
  • Pharmacokinetic data from Part A and the first two cohorts of Part B confirmed rapid absorption and dose-related plasma exposure for oral ANEB-001.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder.
  • Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial ( www.clinicaltrials.gov/ct2/show/NCT05282797 ) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration.